Johnson & Johnson Says New Data Support Nipocalimab's Long-Term Disease Control in Myasthenia Gravis

MT Newswires Live04-08

Johnson & Johnson (JNJ) said Tuesday that the latest results from a trial of the investigational nipocalimab plus standard of care administered to adults with generalized myasthenia gravis showed "maintained improvements" over 84 weeks.

The company said results from the additional analyses of its phase 3 study and the ongoing open-label extension evaluating the long-term efficacy and safety of nipocalimab produced "sustained reductions" in total immunoglobulin G.

Up to 128 weeks and 180 patient-years of follow-up in the open-label extensions "confirm a safety profile consistent" with its phase 3 study, Johnson & Johnson said.

The nipocalimab plus standard of care group showed four times greater odds of improving and maintaining the strength and function of different muscle groups, compared with placebo plus standard of care in the 24-week double-blind phase of the study.

Myasthenia gravis is a disease in which the immune system mistakenly makes antibodies, potentially blocking or disrupting normal signaling from nerves to muscles.

The company's shares were up 2.8% in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2525865508?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-04-08 17:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525865508","market":"us","top_or_hot":-1,"title":"Johnson & Johnson Says New Data Support Nipocalimab's Long-Term Disease Control in Myasthenia Gravis","media":"MT Newswires Live","content":"<html><body><p> Johnson &amp; Johnson (JNJ) said Tuesday that the latest results from a trial of the investigational nipocalimab plus standard of care administered to adults with generalized myasthenia gravis showed \"maintained improvements\" over 84 weeks.</p><p>The company said results from the additional analyses of its phase 3 study and the ongoing open-label extension evaluating the long-term efficacy and safety of nipocalimab produced \"sustained reductions\" in total immunoglobulin G.</p><p>Up to 128 weeks and 180 patient-years of follow-up in the open-label extensions \"confirm a safety profile consistent\" with its phase 3 study, Johnson &amp; Johnson said.</p><p>The nipocalimab plus standard of care group showed four times greater odds of improving and maintaining the strength and function of different muscle groups, compared with placebo plus standard of care in the 24-week double-blind phase of the study.</p><p>Myasthenia gravis is a disease in which the immune system mistakenly makes antibodies, potentially blocking or disrupting normal signaling from nerves to muscles.</p><p>The company's shares were up 2.8% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson Says New Data Support Nipocalimab's Long-Term Disease Control in Myasthenia Gravis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson Says New Data Support Nipocalimab's Long-Term Disease Control in Myasthenia Gravis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-08 17:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Johnson &amp; Johnson (JNJ) said Tuesday that the latest results from a trial of the investigational nipocalimab plus standard of care administered to adults with generalized myasthenia gravis showed \"maintained improvements\" over 84 weeks.</p><p>The company said results from the additional analyses of its phase 3 study and the ongoing open-label extension evaluating the long-term efficacy and safety of nipocalimab produced \"sustained reductions\" in total immunoglobulin G.</p><p>Up to 128 weeks and 180 patient-years of follow-up in the open-label extensions \"confirm a safety profile consistent\" with its phase 3 study, Johnson &amp; Johnson said.</p><p>The nipocalimab plus standard of care group showed four times greater odds of improving and maintaining the strength and function of different muscle groups, compared with placebo plus standard of care in the 24-week double-blind phase of the study.</p><p>Myasthenia gravis is a disease in which the immune system mistakenly makes antibodies, potentially blocking or disrupting normal signaling from nerves to muscles.</p><p>The company's shares were up 2.8% in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2525865508","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525865508","pubTimestamp":1744104634,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Johnson & Johnson  said Tuesday that the latest results from a trial of the investigational nipocalimab plus standard of care administered to adults with generalized myasthenia gravis showed \"maintained improvements\" over 84 weeks.The company said results from the additional analyses of its phase 3 study and the ongoing open-label extension evaluating the long-term efficacy and safety of nipocalimab produced \"sustained reductions\" in total immunoglobulin G.Up to 128 weeks and 180 patient-years of follow-up in the open-label extensions \"confirm a safety profile consistent\" with its phase 3 study, Johnson & Johnson said.The nipocalimab plus standard of care group showed four times greater odds of improving and maintaining the strength and function of different muscle groups, compared with placebo plus standard of care in the 24-week double-blind phase of the study.Myasthenia gravis is a disease in which the immune system mistakenly makes antibodies, potentially blocking or disrupting nor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"强生称新数据支持Nipocalimab对重症肌无力的长期疾病控制","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1},"content_text":"Johnson & Johnson (JNJ) said Tuesday that the latest results from a trial of the investigational nipocalimab plus standard of care administered to adults with generalized myasthenia gravis showed \"maintained improvements\" over 84 weeks.The company said results from the additional analyses of its phase 3 study and the ongoing open-label extension evaluating the long-term efficacy and safety of nipocalimab produced \"sustained reductions\" in total immunoglobulin G.Up to 128 weeks and 180 patient-years of follow-up in the open-label extensions \"confirm a safety profile consistent\" with its phase 3 study, Johnson & Johnson said.The nipocalimab plus standard of care group showed four times greater odds of improving and maintaining the strength and function of different muscle groups, compared with placebo plus standard of care in the 24-week double-blind phase of the study.Myasthenia gravis is a disease in which the immune system mistakenly makes antibodies, potentially blocking or disrupting normal signaling from nerves to muscles.The company's shares were up 2.8% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2525865508"}